leadXpro AG
leadXpro AG is a Swiss biotechnology company specializing in structure-based drug discovery for membrane proteins.
About
leadXpro AG is a Swiss lead discovery company focused on developing next-generation lead compounds for challenging membrane protein drug targets such as GPCRs, ion channels, transporters, and enzymes. The company applies advanced biophysical and structure-based methods, including X-ray crystallography and cryo-electron microscopy (cryo-EM), to solve high-resolution structures and accelerate the drug discovery process. leadXpro engages in research collaborations and contract research for pharmaceutical, biotech, and academic partners, offering its expertise throughout all stages of drug discovery, from hit finding and validation to the structure-based optimization of preclinical compounds. It leverages access to large scale research infrastructure at the Paul Scherrer Institute and collaborates with international partners to improve therapies that target membrane proteins and address unmet medical needs.
Products & Services
- Structure-based drug discovery services for membrane proteins
- Generation and structural analysis of membrane proteins (GPCRs, ion channels, transporters, enzymes)
- Cryo-electron microscopy (cryo-EM) services
- X-ray crystallography of difficult membrane targets
- Ligand design and biophysical characterization
- Preclinical drug compound development and optimization
- Discovery and optimization of small molecule and biotherapeutic lead compounds
- Collaborative R&D projects with pharma, biotech, and academia
- Production of high-quality membrane protein samples
- Screening and validation of drug candidates
- Development of proprietary preclinical compounds
Use Cases & Case Studies
- Solved the world’s first cryo-EM structure of the human TRPV4 ion-channel in complex with an agonist (with Bayer)
- Solving the structure of bacterial transporter LptDE for antibiotic design (with Basel Biozentrum and others)
- Enabling selective antagonist design for CC Chemokine receptor 2A (with Boehringer Ingelheim)
- Discovery, optimization and patenting of selective antagonists of the A2B adenosine receptor
Partnerships & Collaborations
- Cumulus Oncology
- Alipheron
- Golgi Neurosciences
- Astex Pharmaceuticals
- Bayer
- Axxam
- Sanofi
- Lundbeck
- Boehringer Ingelheim
- University of Zurich
- Creoptix
- InterAx Biotech AG
- Basel Biozentrum
- Swiss National COVID-19 Science Task Force
- Paul Scherrer Institute (PSI)
Awards & Recognition
- CTI Startup Label (2017)